成都中医药大学:靶向肠道菌群以实现精准医疗(综述)
创作:szx 审核:szx 2020年10月29日
  • 肠道菌群可通过直接结合、酶促代谢、合成化合物调控或竞争药物转运蛋白、合成化合物竞争药物代谢酶等方式影响药物的疗效及毒性;
  • 肠道菌群组成及功能差异可影响个体对药物的应答;
  • 基于肠道菌群的生物标志物(菌株/菌种、菌群代谢产物、酶、基因等)可应用于精准医疗,例如粪便硝基还原酶活性与小檗碱治疗高脂血症的生物利用度呈正相关;
  • 除了传统的抗生素、益生菌/元、饮食、粪菌移植等菌群调节方式外,工程菌也可用于调控药物代谢。
主编推荐语
szx
肠道菌群可能影响药物的疗效与毒性,个体间菌群组成及功能的不同可能导致的药物应答的差异。成都中医药大学的彭成团队在Theranostics上发表的一篇综述文章,详细讨论了以下几个方面:肠道菌群影响药物疗效及毒性的机制、肠道菌群变化导致的药物应答差异、基于肠道菌群的生物标志物用于患者分层及治疗决策、个性化调控肠道菌群以改善药物应答的策略。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Theranostics [IF:8.579]

Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs

靶向肠道菌群以实现精准医疗:关注药物的疗效与毒性

10.7150/thno.47289

2020-09-14, Review

Abstract & Authors:展开

Abstract:收起
Intra- and interindividual variation in drug responses is one major reason for the failure of drug therapy, drug toxicity, and even the death of patients. Precision medicine, or personalized medicine, is a field of medicine that customizes an individual's medical diagnosis and treatment based on his/her genes, microbiomes, environments, etc. Over the past decade, a large number of studies have demonstrated that gut microbiota can modify the efficacy and toxicity of drugs, and the extent of the modification varies greatly from person to person because of the variability of the gut microbiota. Personalized manipulation of gut microbiota is an important approach to rectify the abnormal drug response. In this review, we aim to improve drug efficacy and reduce drug toxicity by combining precision medicine and gut microbiota. After describing the interactions between gut microbiota and xenobiotics, we discuss (1) the effects of gut microbiota on drug efficacy and toxicity and the corresponding mechanisms, (2) the variability of gut microbiota, which leads to variation in drug responses, (3) the biomarkers used for the patient stratification and treatment decisions before the use of drugs, and (4) the methods used for the personalized manipulation of gut microbiota to improve drug outcomes. Overall, we hope to improve the drug response by incorporating the knowledge of gut microbiota into clinical practice.

First Authors:
Wuwen Feng

Correspondence Authors:
Cheng Peng

All Authors:
Wuwen Feng,Juan Liu,Hui Ao,Shijun Yue,Cheng Peng

评论